drugset

drugset / Trial / NCT01475136

A Study of LY2140023 in Hepatically-Impaired Participants

NCT01475136 ↗

Phase 1 Completed 37 enrolled Denovo Biopharma LLC

NaSingle-groupOpen-labelBasic science

Summary

This study will explore how liver impairment affects blood levels of LY2140023 (a prodrug) and its active metabolite (LY404039).

Timeline

Start: 2011-11
Primary completion: 2012-12
Completion: 2012-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2140023	Unknown	80 mg	Oral

Indications